Travere Therapeutics earnings were -$21.4M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest TVTX earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$37.1M, down 1,459.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, TVTX reported annual earnings of -$25.5M, with -92.1% growth.
Travere Therapeutics Earnings Reports & History FAQ
What were Travere Therapeutics's earnings last quarter?
On TVTX's earnings call on Invalid Date, Travere Therapeutics (NASDAQ: TVTX) reported Q1 2026 earnings per share (EPS) of -$0.40, up 14.89% year over year. Total TVTX earnings for the quarter were -$37.10 million. In the same quarter last year, Travere Therapeutics's earnings per share (EPS) was -$0.47.
Is Travere Therapeutics profitable or losing money?
As of the last Travere Therapeutics earnings report, Travere Therapeutics is currently losing money. Travere Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$21.42 million, a 90.55% decrease year over year.
What was TVTX's earnings growth in the past year?
As of Travere Therapeutics's earnings date in Invalid Date, Travere Therapeutics's earnings has grown year over year. TVTX earnings in the past year totalled -$21.42 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.